The Future, Low Temperature Spray Dry / Perfect Microencapsulation

Fluid Air’s patent-pending PolarDry Electrostatic Spray Dryers utilizes revolutionary electrostatic

Technology which allows for low temperature spray drying, near perfect encapsulation and selective agglomeration in the creation of particles. Years of development and testing have proven that electrostatic spray dry technology has many advantages for the pharmaceutical industry that include superior morphology, longer shelf life, non-reactive processing, minimal emissions and low energy consumption compared to traditional spray drying processes.

PolarDry’s promising technology will open a whole new branch of Active Pharmaceutical Ingredients that previously could not be produced in a powder form due to the required high temperatures of traditional spray drying. Using the PolarDry technology, particles can be produced at ambient to 80° C inlet conditions. This is possible since the electrostatic effect drives highly polarizable water/solvent to the outer shell of the particle making it easy to dry the particle. Low temperature processing eliminates ingredient loss, degradation, or denaturalization.

At the same time, less polarizable active and excipients are driven to the core, due to the electrostatic effect, microencapsulating the active and virtually eliminating surface active, resulting in stunning encapsulation efficiency. Perfect encapsulation promises more efficient, effective products and new avenues for drug delivery. This single step process eliminates the need for secondary operations, reducing operation costs and simplifying regulatory requirements.